Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer, G.; Nelson, M.; Lazzarin, A.; Konourina, I.; Hoepelman, A.; Lampiris, H.; Hirschel, B.; Tebas, P.; Raffi, F.; Trottier, B.; C. Bellos, Nicholaos; Saag, M.; Cooper, D.; Westby, M.; Tawadrous, M.; Sullivan, J.; Ridgway, C.; Dunne, M.; Felstead, S.; Mayer, H.; van der Ryst, E.

doi:10.1056/NEJMoa0803154

Public

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Shared by NobleBlocks on Oct 2, 2008 • 12:00 AM UTC

Authors:

G. Fätkenheuer

M. Nelson

A. Lazzarin

Abstract

BACKGROUND We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better characterize the efficacy and safety of maraviroc in key subgroups of patients. METHODS We anal...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!